-
Site License
-
Site License
-
Enterprisewide
-
Enterprisewide
Multi Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in China
Frost & Sullivan, December 2009, Pages: 62
This research service aims to provide an update on the epidemiology of Hepatitis C, including the prevalence and incidence, Market Engineering measurements, and government initiatives. It also covers patient source, load, and forecasts, while also outlining the key treaters involved. Current diagnostic methods are presented, followed by treatment regimens, their cost, and upcoming product launches. Clinical trials highlighting research into new treatments are also provided, along with an analysis of the pipeline. Additionally, there is a competitive analysis which includes the market structure, major participants, and future trends. This service covers the Hepatitis C therapeutics market in China.
This Frost & Sullivan research service titled Multi Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in China provides an overview of the market, government initiatives, patient load and classification, patient forecasts, treatment regimens, product launches, and challenges faced by physicians.
This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Services program. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services program ensures that you and your Growth Team™ are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth.
Market Overview
Better Understanding of Diagnosis Paves the Way for Novel Treatments in the Hepatitis C Therapeutics Market in China
Sustained efforts to raise awareness of Hepatitis C have increased the number of diagnosed cases and expanded the pool of patients available for treatment. Most Hepatitis C cases in China come from injecting drug users and those who receive contaminated blood products. Prevalence of Hepatitis C is higher among injecting drug users in several southern provinces in China, while improper blood screening is more prevalent in the rural areas of the country. According to the Chinese Medical Association and Chinese Foundation for Hepatitis Prevention and Control (CFHPC), the number of people infected with Hepatitis C virus (HCV) in China is increasing. "Although there is a high diagnosis rate in China, only a paltry 10 percent of diagnosed patients pursue treatment because patient and physician awareness of the disease is still generally low," notes the analyst of this research service.
The debilitating side effects, frequent dosing, and lackluster efficacy of the existing HCV treatment lower compliance among patients, especially those afflicted with Genotype 1. The current treatment regimen of Pegylated Interferon and Ribavirin for Hepatitis C comes with strong side effects, such as lowered blood platelet count, depression, and hemolytic anemia, while also having a lowered efficacy in Genotype 1 patients. This has spurred the exploration of more effective treatments. "According to physicians, those afflicted with Hepatitis C Genotype 1 have a sustained viral response of 40-50 percent to current therapy," says the analyst. "With 70 percent of those diagnosed with Hepatitis C in China having the Genotype 1 strain, the current drug offerings are unable to capture a sizeable portion of the market." At present, no interferon-based drug for the treatment of Hepatitis C has been included in the National Reimbursement List in China. This situation is further worsened by the fact that approximately 40 percent of the urban population and 80 percent of the rural population are uninsured, indicating that they may not be able to afford costly treatment.
Awareness and diagnosis efforts have increased, although they have been mostly targeted toward urban areas, while most of the population is concentrated in the rural areas. The combination of these factors represent missed treatment opportunities and thus, market share. Companies must offer treatment options that expedite efficiency, have fewer side effects, and are cost efficient. Public and private organizations, including pharmaceutical companies, must participate in disease awareness for Hepatitis C. Campaigns are needed to raise awareness of the virus and how infection can be prevented, diagnosed, and treated. Information on the current treatments available will enable patients to understand the nuances of the disease and be more receptive toward such treatment methods. Refined versions of current HCV drugs, oral formulations of small molecule inhibitors, and the new drug class known as protease inhibitors are in the development pipeline and represent the future of HCV treatment. New treatment options must be launched to capture this growing market.
1 | EXECUTIVE SUMMARY
- - Overview
- - - 1. Executive Summary China
- 2 | HEPATITIS C THERAPEUTICS MARKET
- - Market Overview
- - - 1. Introduction
- - - 2. Context for the Study
- - - 3. Scope and Segmentation of the Study
- - - 4. Methodology
- - - 5. Restraints in Forecast
- 3 | CHINESE HEPATITIS C THERAPEUTIC MARKET
- - Market Overview
- - - 1. Introduction
- - - 2. Marketing Engineering Measurements
- - - 3. Government Initiatives
- - Hepatitis C Patients
- - - 1. Patient Source and Quantification
- - - 2. Key Treaters and Patient Flow
- - - 3. Patient Forecasts
- - Diagnosis and Treatment
- - - 1. Diagnostic Test and Monitoring
- - - 2. Treatment Regimens
- - - 3. Cost of Treatment
- - - 4. Product Launches
- - - 5. Clinical Trials
- - Competitive Analysis
- - - 1. Competitive Structure
- - - 2. Future Trends
- - - 3. Challenges Faced by Physicians
- 4 | APPENDIX
- - Supporting References
- - - 1. Appendix
List of Figures
-
Chapter 3
- Hepatitis C Therapeutics Market: Prevalence of Hepatitis C (China), 2006-2016
- Hepatitis C Therapeutics Market: Incidence of Hepatitis C (China), 2006-2016
- Hepatitis C Therapeutics Market Patient Classification of Current HCV Patients Based on HCV Condition (China), 2009
- Hepatitis C Therapeutics Market: Categorization of Patients Based on Treatment Choices (China), 2009
- Hepatitis C Therapeutics Market: Patient Classification of Current HCV Patients Based on Route of Transmission (China), 2009
- Hepatitis C Therapeutics Market: Percent of Patients who are Treatment Naïve, Currently Treated with Interferon-based Therapy and Previously Treated with Interferon-based Therapy (China), 2009
- Hepatitis C Therapeutics Market: Categorization of Patients Previously Treated with Interferons (China), 2009
- Hepatitis C Therapeutics Market: Categorization of Patients Based on Genotype (China), 2009
- Hepatitis C Therapeutics Market: Diagnosed Hepatitis C Patients Forecasts (China), 2006-2016
- Hepatitis C Therapeutics Market: Market Drivers for Patients Treated Ranked in Order of Impact (China), 2010-2016
- Hepatitis C Therapeutics Market: Market Restraints for Patients Treated Ranked in Order of Impact (China), 2010-2016
- Hepatitis C Therapeutics Market: Treated Hepatitis C Patients Forecasts (China), 2006-2016
- Hepatitis C Therapeutics Market: Available, Acute and Chronic Hepatitis C Treated Patients Forecasts (China), 2006-2016
- Hepatitis C Therapeutics Market: Circumstances that Prompt Physicians to Test Patients for HCV (China), 2009
- Hepatitis C Therapeutics Market: Key Diagnostic Tests Required Prior to Initiating Therapy for Infection with HCV (China), 2009
- Hepatitis C Therapeutics Market: Tests Used and The Key Clinical Indicators that Confirm a Patient's Progression from Acute HCV to Chronic Disease (China), 2009
- Hepatitis C Therapeutics Market: Percent of Usage of Pegasys and Pegintron (China), 2009
- Hepatitis C Therapeutics Market: Treatment Regimen for Acute HCV Patients (China), 2009
- Hepatitis C Therapeutics Market: Treatment Regimen for Genotype 1 Chronic HCV Patients (China), 2009
- Hepatitis C Therapeutics Market: Treatment Regimen for Genotype 2 and 3 Chronic HCV Patients (China), 2009
- Hepatitis C Therapeutics Market: Advantages and Drawbacks of Drugs Prescribed (China), 2009
- Hepatitis C Therapeutics Market: Average Monthly Cost of Treatment of Various Regimens (China), 2009
- Hepatitis C Therapeutics Market: List of Clinical Trials Conducted by Phase, Patient Age, Stage, Drug, and Sponsor (China), 2009
- Hepatitis C Therapeutics Market: List of Interferons in Development (World), 2009
- Hepatitis C Therapeutics Market: List of Interferons in Development (World), 2009
- Hepatitis C Therapeutics Market: List of Small-molecule Antivirals in Development (World), 2009
- Hepatitis C Therapeutics Market: List of Non-interferons in Development (World), 2009
- Hepatitis C Therapeutics Market: Competitive Structure (China), 2009
- Hepatitis C Therapeutics Market: Treatment Forecasts (China), 2009-2016
Chapter 4
- Hepatitis C Therapeutics Market: Total Population and Population Growth Rate (China), 2006-2016
- Hepatitis C Therapeutics Market: Assumptions Used in Estimating Patient Forecasts (China), 2009
- Hepatitis C Therapeutics Market: Assumptions Used in Estimating Treatment Forecasts (China), 2009-
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
